The present invention concerns correlation between plasma t-tau, p-tau and Aβ1-42 levels and AD-associated tau pathology in brain. The present invention also relates to methods for determining a level of brain tau accumulation in a brain region of a subject, diagnosing a tau positive subject and treating the same, assessing a progression of a sign or a symptom of Alzheimer disease and treating the same, detecting a sign or a symptom of Alzheimer disease in a subject and treating the same, determining brain glucose metabolism in a subject, determining a neurodegeneration level in a subject, and determining cognitive function in a subject, and diagnostic kits for determining a tau positive patient, diagnosing a tau positive subject or detecting a sign or a symptom of Alzheimer disease in a subject.
METHOD OF DIAGNOSING AND TREATING ALZHEIMER DISEASE USING PLASMA TAU LEVEL IN CONJUNT ION WITH BETA-AMYLOID LEVEL AS DIAGNOSTIC INDEX